-
Summary of targets and bispecific antibodies for the treatment of hematological malignancies (1)
Time of Update: 2021-05-21
Table 1 Bispecific antibody acute lymphoblastic leukemia for the treatment of hematological malignancies Even after high-intensity salvage chemotherapy and hematopoietic stem cell transplantation, clinical results of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) Still very poor.
-
Sci Adv | Liposomes help in situ tumor immunotherapy
Time of Update: 2021-05-21
In addition, this liposome also enhances the cross-presentation of antigens and promotes the activation of interferon gene stimulating protein (STING), which has achieved significant effects in the treatment of mouse melanoma tumor models.
-
K drug hits esophageal cancer across the board, leading a new standard of treatment
Time of Update: 2021-05-21
*For medical professionals to read and refer to the CSCO guidelines, PD-1 monoclonal antibody is recommended for the first-line treatment of advanced esophageal cancer. In June 2020, two PD-1 immune
-
Cancer cells put "poison" to suppress T cells!
Time of Update: 2021-05-21
They found that extracellular vesicles (TEVs) containing miR-424 secreted by intestinal cancer cells can be taken up by infiltrating immune cells in the tumor microenvironment, resulting in a decrease in the expression of CD28 and CD80 of T cells and dendritic cells (DCs).
-
Experts comment on Nat Nanotech| Gu Zhen's team develops anti-tumor patch, in situ catalyzed reaction to produce anti-cancer drugs
Time of Update: 2021-05-21
The research team used polyvinyl alcohol (PVA) as the matrix of the microneedle patch, mixed with titanium dioxide nanosheets deposited by palladium nanoparticles, and prepared a bio-orthogonal catalytic device that can increase efficiency, reduce toxicity, and is easy to use (Figure 2) Anti-cancer drugs can be produced in situ through a catalytic reaction where the patch is used.
-
Nature Medicine | Qian Junbin et al. Reveal the response mechanism of breast cancer immunotherapy and propose new methods for predicting efficacy
Time of Update: 2021-05-21
On May 6, 2021, Researcher Qian Junbin from the Obstetrics and Gynecology Hospital of Zhejiang University School of Medicine, Professor Ann Smeets from Leuven University Hospital in Belgium, and Professor Diether Lambrechts from the VIB Institute published an article A single-cell map of Nature Medicine intratumoral changes during anti-PD1 treatment of patients with breast cancer.
-
The end result of MSI standardized testing: 4 major guidelines/consensus updated from 2021, talk about the site selection of MSI testing
Time of Update: 2021-05-21
From the four latest editions of the guidelines/consensus above, we can see that the current gold standard method for MSI detection is PCR + capillary electrophoresis, and there are only two site selections, one is NCI's 2B3D Panel, and the other is Promega Panel of 5 single nucleotides.
-
The most complete summary: Do you need adjuvant treatment after lung cancer surgery?
Time of Update: 2021-05-21
The Phase IB ADAURA study [9] showed that the adjuvant treatment of osimertinib for 3 years after complete tumor resection of EGFR mutation-positive stage IB patients can reduce the risk of disease recurrence or death by 61%.
-
There are new discoveries in the prediction of the efficacy of lung cancer immunotherapy; TROP-2 antibody-conjugated drugs in the treatment of triple-negative breast cancer DCR reaches 95%|Tumor News
Time of Update: 2021-05-21
*Only for medical professionals to read for reference 1 minute a day, give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can add th
-
Lancet: Is it necessary to screen the "female killer" ovarian cancer population?
Time of Update: 2021-05-21
The results showed that during the median follow-up time of 11±1 years, the absolute proportion of women with ovarian cancer, fallopian tube cancer, and peritoneal cancer diagnosed with stage I or II disease in the MMS group increased by 13% compared with the no-screening group.
-
The first leukemia child to receive CAR-T treatment, cancer-free for nine years!
Time of Update: 2021-05-21
After receiving treatment, Emily developed cytokine release syndrome, also known as cytokine storm, which is a common acute side effect of CAR-T therapy.
Pineapple Factor "The first child cured by CAR-T therapy, has survived cancer-free for 9 years!
-
Express | Triple-negative breast cancer disease control rate reaches 95%, TROP2-ADC preliminary clinical results are positive
Time of Update: 2021-05-21
▎The content team editor of WuXi AppTec recently, researchers announced for the first time that the antibody-conjugated drug (ADC) datopotamab deruxtecan (Dato-DXd), which targets TROP2, will be used in a phase 1 clinical trial for the treatment of triple-negative breast cancer (TNBC).
-
Hengrui Medicine's CDK 4/6 inhibitor listing application plans to be included in priority review
Time of Update: 2021-05-21
On May 10, according to the latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, Hengrui Medicine’s CDK4/6 inhibitor dalpiciclib (SHR6390 table
-
Professor Liu Hongxu: Osimertinib adjuvant therapy brings good news to more patients after early NSCLC surgery
Time of Update: 2021-05-21
At present, osimertinib has obtained indications for adjuvant therapy for early stage non-small cell lung cancer (NSCLC) patients in China based on the research results of ADAURA.
-
Express | Treatment of early-stage triple-negative breast cancer patients, blockbuster PD-1 inhibitors reach dual phase 3 clinical endpoints
Time of Update: 2021-05-21
(MSD) announced that its blockbuster anti-PD-1 therapy Keytruda in the treatment of high-risk early triple-negative breast cancer (TNBC) patients in the pivotal phase 3 clinical trial KEYNOTE-522 Reached the dual primary endpoint.
-
BeiGene: NMPA approves the PARP inhibitor Baihuize® for advanced ovarian cancer that has previously been treated
Time of Update: 2021-05-21
The most common adverse reactions (≥10%) reported in this key phase 2 clinical trial in China were anemia, leukopenia, nausea, neutropenia, vomiting, thrombocytopenia, loss of appetite, fatigue, abdominal pain, and elevated ALT.
-
NGS protocol and clinical application of multiple myeloma
Time of Update: 2021-05-21
Multiple myeloma-Landscape 2018 published a study NGS detection template included a total of 246 genes, a total of 215 genes were detected to have mutations in 418 patients, of which 106 are clear oncogenes, and the possible oncogenes are 71.
-
Why do some cancer cells prefer to metastasize to the bones?
Time of Update: 2021-05-21
▲The metabolic pathway mediated by EZH2 in the bone microenvironment affects ER signal expression and produces tolerance to endocrine therapy (picture source: reference [2]) It is worth noting that the interaction with osteoblasts also triggers Changes in gene expression make cancer cells have stem cell-like characteristics, such as uncontrolled self-renewal and differentiation into various cell types.
-
"Nature": Sequencing technology has made important progress, refreshing the understanding of cancer and aging
Time of Update: 2021-05-21
Robert Osborne, who was responsible for developing this method, pointed out that the improved accuracy of single-cell sequencing allowed scientists to achieve the first Research on DNA changes in human tissues.
-
Lancet oncol: The anti-tumor activity of Cemiplimab in locally advanced basal cell carcinoma is promising
Time of Update: 2021-05-21
1016/S1470-2045(21)00126-1" target="_blank" rel="noopener">Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial .
1016/S1470-2045(21)00126-1" target="_blank" rel="noopener">Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial in this message
